介入化疗加栓塞治疗联合二期手术治疗中晚期肝癌的效果观察  

Effects of Transcatheter Arterial Chemoembolization Allied with Secondary Operation in Treating Hepatocellular Carcinoma

作　　者：丁勇[1] 李长波[2] 王予东[1] 邱娜[1] 

机构地区：[1]河南大学医学院,河南省开封市475000 [2]河南大学淮河医院

出　　处：《中国全科医学》2011年第29期3393-3395,共3页Chinese General Practice

摘　　要：目的观察介入化疗加栓塞治疗(TACE)+二期手术治疗中晚期肝癌患者的预后情况。方法对128例中晚期原发性肝癌患者先进行TACE,根据治疗后患者是否行手术治疗进行分组:接受二期手术者为A组(60例),不接受二期手术者为B组(68例)。比较A组与B组患者生存时间的差别,并进行对比分析。结果 TACE后,A组与B组患者的1～2年生存率间差异无统计学意义(P>0.05),但A组患者3年及3年以上生存率显著高于B组,差异有统计学意义(P<0.05)。A组OkudaⅠ期患者的生存率显著高于B组,差异有统计学意义(P<0.05);两组Oku-daⅡ期患者的生存率比较,差异无统计学意义(P>0.05)。结论中晚期原发性肝癌OkudaⅠ期患者经TACE后若具备二期手术条件,应进行二期手术治疗,有助于延长患者的生存时间;但对于OkudaⅡ期患者,保守治疗与手术治疗对患者的生存期无影响。Objective To observe the prognosis of patients received transcatheter arterial chemoembolization（TACE） allied with secondary operation. Methods A total of 128 cases of primary liver cancer underwent transcatheter arterial chemoembolization.These patients were divide into two groups with group A（60 cases） received subsequent secondary operation and group B（68 cases） received no secondary operation.Duration of survival were compared between the two groups. Results After TACE,no significant differences existed in 1～2 years survival rates between group A and group B（P0.05）,while survival rates after 3 years or more were significantly different between the two groups（P0.05）.Patients of Okuda phase Ⅰ displayed higher survival rate in group A compared with group B（P0.05）;survival rates of Okuda phase Ⅱ patients were not significantly different between the two groups（P0.05）. Conclusion Secondary operation in Okuda Ⅰ patients of primary liver carcinoma is preferable,if possible,with the hope to prolong the survival of the patients.As long as patients of Okuda phase Ⅱ are concerned,conservative treatment and surgical treatment showed similar survival length.

关 键 词：肝肿瘤 介入化疗加栓塞治疗 外科手术 治疗结果 

分 类 号：R735.7[医药卫生—肿瘤]